STI Stock Trade Intelligence
AGN

ARGENICA THERAPEUTICS LIMITED

Health Care · ASX:AGN
$0.1200
0.00%
Market cap
$15M
Turnover
—
Last price
$0.1200
Day change
0.00%
Announcements
12
Range, past year
Open 0.240 · Low 0.087 · Now 0.120 · High 0.850
Open AGN in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

AGN momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
30/100
Wyckoff phase
Accumulation6d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+9.1%
1 Month
-20.0%
1 Year
-52.0%
RSI
50
Avg daily range
8.6%

ARGENICA THERAPEUTICS LIMITED scores 30 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 6 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently matching and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -53.7%
  • High volatility (ATR 8.6%)
  • Risk rating: Very High
  • Composite downside risk elevated
AGN appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

AGN announcements

Recent price-sensitive releases.
  • 2026-10-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-20 New Mechanism Findings Offer Insights Into Phase 2 Signal Progress Report
  • 2026-08-26 Appendix 4E & Annual Report to 30 June 2026 Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-07-24 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-16 ARG007 Shows Significant Neuroprotection in Concussion Study
  • 2026-06-11 ARG007 (Xaranetide) Completes All Three FDA Requested Assays
  • 2026-06-10 WHO Confirms Xaranetide as INN for ARG-007
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.